{
    "clinical_study": {
        "@rank": "36994", 
        "acronym": "ADDLIST", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 3 x 1 tablet, given everyday for 28 days of study period"
            }, 
            {
                "arm_group_label": "DLBS1033", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized, double-blind, and controlled clinical study to\n      investigate the effects of DLBS1033 in conjunction with standard therapy compared to\n      standard therapy alone in acute ischemic stroke patients. It is hypothesized that the\n      improvement in functional outcomes as measured by NIHSS and BI as well as the improvement in\n      haemostatic parameters as measured by thrombocyte aggregation test (TAT), fibrinogen, and\n      d-dimer in DLBS group will be significantly greater than those in the control group."
        }, 
        "brief_title": "DLBS1033 for Acute Ischemic Stroke Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Stroke", 
            "Partial Anterior Circulation Infarction", 
            "Lacunar Infarction by Bamford Criteria"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects in this study will be screened consecutively and eligible subjects will be\n      randomized into two groups and receive the investigational drug, DLBS1033 at a dose of 490\n      mg three times daily or its placebo in addition to standard therapy for 28-days course of\n      therapy. Standard therapy used in this study will consist of: aspirin 80 mg, simvastatin 20\n      mg, and vitamin B complex.\n\n      After hospital admission and diagnosis, patient will be handled as per acute ischemic stroke\n      management in each study site. Right after the patient is confirmed eligible to the study,\n      the treatment(s) will be switched immediately into the study treatments. Clinical and\n      laboratory examinations to evaluate the investigational drug's efficacy will be performed at\n      baseline and 3, 7,14, and 28 days after study medication initiation; while safety\n      examinations will be performed at the same time point, but 3 and 14 days after study\n      medication initiation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent from the patients or patients' legally acceptable\n             representatives (must be obtained before any trial related activities).\n\n          -  Male or female subjects with age of 18-65 years at Screening.\n\n          -  Patients clinically diagnosed having acute ischemic stroke attack and confirmed by CT\n             scan.\n\n          -  Patients with cerebral infarction subtypes of PACI or LACI as classified by Bamford\n             criteria.\n\n          -  Patients with moderate condition based on National Institutes of Health Stroke Scale\n             (NIHSS) score of 5-15.\n\n          -  Patients present at hospital and receiving first dose of study medication within 72\n             hours after the onset of the stroke symptoms.\n\n          -  Able to take oral medication.\n\n          -  Patients or patients' legally acceptable representatives are able and willing to\n             record adverse events in a diary.\n\n          -  Patients or patients' legally acceptable representatives have the ability to comply\n             with the trial protocol.\n\n        Exclusion Criteria:\n\n          -  For females of childbearing potential: pregnancy and lactation period. Patients must\n             accept pregnancy tests during the trial if menstrual cycle is missed. Fertile\n             patients must use effective contraception.\n\n          -  History of hemorrhagic stroke within the last 3 months.\n\n          -  Patients with seizure at the onset of stroke or with regular medication for\n             seizure/epilepsy.\n\n          -  Current or regular use (within the last 1 month) of oral anticoagulants,\n             antiplatelets other than study medication, and herbal medicines.\n\n          -  Patients who have received tissue plasminogen activator (TPA) within 24 hours to\n             Screening.\n\n          -  History of serious head injury within the last 3 months.\n\n          -  History of major surgery within the last 3 months.\n\n          -  Recent serious cardiovascular conditions, such as myocardial infarction and heart\n             atrial fibrillation as demonstrated by electrocardiography (ECG).\n\n          -  History of congestive heart failure and aortic dissection.\n\n          -  Presence of severe renal and hepatic dysfunction, defined as serum creatinine level >\n             3x upper limit of normal (ULN) or history of hemodialysis, and any of serum ALT, AST,\n             Gamma-GT level of > 3x ULN, respectively.\n\n          -  Presence of acute SIRS.\n\n          -  Presence of chronic infections.\n\n          -  Patients with higher risks of bleeding.\n\n          -  Subjects with uncontrolled hypertension (systolic blood pressure > 185 mmHg or\n             diastolic blood pressure > 110 mmHg).\n\n          -  Subjects with random plasma glucose \u2265180 mg/dL and HbA1c \u2265 7.0% at Screening.\n\n          -  Known or suspected hypersensitivity to the trial product or related products.\n\n          -  Participation in any other clinical studies within 30 days prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133521", 
            "org_study_id": "DLBS1033-0111"
        }, 
        "intervention": [
            {
                "arm_group_label": "DLBS1033", 
                "description": "Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet", 
                "intervention_name": "DLBS1033", 
                "intervention_type": "Drug", 
                "other_name": "Disolf"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBS1033", 
            "acute ischemic stroke", 
            "NIHSS", 
            "Barthel Index"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dodik_tugasworo@yahoo.com", 
                    "last_name": "Dodik Tugasworo, Sp.S(K), MD"
                }, 
                "contact_backup": {
                    "email": "ratihapsoro@gmail.com", 
                    "last_name": "Ratih V Octaviani, Sp.S, MSi., Med"
                }, 
                "facility": {
                    "address": {
                        "city": "Semarang", 
                        "country": "Indonesia", 
                        "state": "Central Java"
                    }, 
                    "name": "Neurology Department, Dr. Kariadi General Hospital"
                }, 
                "investigator": {
                    "last_name": "Ratih V Octaviani, Sp.S, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "wijoto_neurologi@yahoo.co.id", 
                    "last_name": "Wijoto, Sp.S(K), MD"
                }, 
                "contact_backup": {
                    "email": "achmad_sani@yahoo.co.id", 
                    "last_name": "Achmad Firdaus Sani, Sp.S(K), FINS"
                }, 
                "facility": {
                    "address": {
                        "city": "Surabaya", 
                        "country": "Indonesia", 
                        "state": "East Java"
                    }, 
                    "name": "Stroke/Cerebrobascular Division, Neurology Department, Dr. Soetomo Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Paulus Sugianto, Sp.S(K), MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Achmad F Sani, Sp.S, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "nari_ade@yahoo.com", 
                    "last_name": "Diatri N Lastri, Sp.S(K), MD"
                }, 
                "contact_backup": {
                    "email": "mkurniawan.md@gmail.com", 
                    "last_name": "Mohammad Kurniawan, Sp.S, FICA"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia"
                    }, 
                    "name": "Cerebrovascular, Neurosonology, and Intervention, Neurology Division, Neurology Department, Dr. Cipto Mangunkusumo Hospital"
                }, 
                "investigator": {
                    "last_name": "Mohammad Kurniawan, Sp.S, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients", 
        "overall_contact": {
            "email": "fenny.yudiarto@yahoo.com", 
            "last_name": "Fenny L Yudiarto, Sp.S(K), MD"
        }, 
        "overall_contact_backup": {
            "email": "mh.machfoed@gmail.com", 
            "last_name": "Hasan Machfoed, Prof., Sp.S(K), MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Neurology Department Dr. Soetomo Hospital", 
                "last_name": "Hasan Machfoed, Prof, Sp.S(K), MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Indonesia's Neurologists Organization (Perdossi)", 
                "last_name": "Fenny L Yudiarto, Sp.S(K), MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Neurology Department Dr. Soetomo Hospital", 
                "last_name": "Wijoto, Sp.S(K), MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Neurology Department Dr. Cipto Mangunkusumo Hospital", 
                "last_name": "Diatri N Lastri, Sp.S(K), MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Neurology Department Dr. Kariadi General Hospital", 
                "last_name": "Dodik Tugasworo, Sp.S(K), MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in functional outcomes as measured by National Institutes of Health Stroke Scale (NIHSS) from its baseline value", 
                "measure": "Improvement in NIHSS", 
                "safety_issue": "No", 
                "time_frame": "3, 7, 14, and 28 days"
            }, 
            {
                "description": "Change in functional outcomes as measured by Barthel Index (BI) from its baseline value", 
                "measure": "Improvement in BI", 
                "safety_issue": "No", 
                "time_frame": "3, 7, 14, and 28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133521"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in haemostatic parameter as measured by Thrombocyte Aggregation Test (TAT) from its baseline value", 
                "measure": "Improvement in TAT", 
                "safety_issue": "No", 
                "time_frame": "3, 7, 14, and 28 days"
            }, 
            {
                "description": "Change in haemostatic parameter as measured by fibrinogen level from its baseline value", 
                "measure": "Improvement in fibrinogen level", 
                "safety_issue": "No", 
                "time_frame": "3, 7, 14, and 28 days"
            }, 
            {
                "description": "Change in haemostatic parameter as measured by d-dimer level from its baseline value", 
                "measure": "Improvement in d-dimer level", 
                "safety_issue": "No", 
                "time_frame": "3, 7, 14, and 28 days"
            }, 
            {
                "description": "Liver function measured includes: serum AST, ALT, G-GT, total bilirubin", 
                "measure": "Liver function", 
                "safety_issue": "Yes", 
                "time_frame": "7 and 28 days"
            }, 
            {
                "description": "Renal function measured includes: serum creatinine", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "7 and 28 days"
            }, 
            {
                "description": "Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count", 
                "measure": "Routine hematology", 
                "safety_issue": "Yes", 
                "time_frame": "7 and 28 days"
            }, 
            {
                "description": "Adverse events, including bleeding events, will be observed and carefully evaluated along the course of the study", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 - 28 days"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}